Biogen has paid $125m upfront to get its hands on Chinese company InnoCare’s orelabrutinib, one of a number of promising BTK inhibitors which could transform multiple sclerosis (MS) treatment.
While Biogen is in the news for the ongoing controversy around its newly approved Alzheimer’s drug Aduhelm (aducanumab), it is...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
